Samchundang Pharmaceutical Obtains Japanese Patent for Ophthalmic Pharmaceutical Composition

[Asia Economy Reporter Oh Ju-yeon] Samchundang Pharmaceutical announced on the 16th that it has obtained a Japanese patent related to an ophthalmic pharmaceutical composition. This patent pertains to a technology for ophthalmic formulations containing aflibercept, an active ingredient used as a treatment for macular degeneration, which enables long-term stable maintenance of material properties and biological activity under long-term storage and accelerated conditions.

The company stated, "The original Eylea formulation patent expires later than the material patent, making market entry difficult even after the material patent expires due to the formulation patent." They added, "This patent is for a formulation technology independently developed by our company, unlike the original Eylea's formulation technology, so through patent registration, early market entry aligned with the material patent expiration date is possible."

This patent has been registered domestically in addition to Japan, and applications have been filed in the United States, Europe, China, and other regions, with examinations currently underway.

This content was produced with the assistance of AI translation services.